Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
DiaMedica said it plans to launch the trial later in 2026
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Subscribe To Our Newsletter & Stay Updated
